Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.63 |
| ▸ | CA2 | P00918 | 3/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.57 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.55 |
| ▸ | NME4 | O00746 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.55 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9717434 | 0.92 | MAPK1 (0.71) | CA1CA2MAPK1HDAC2HDAC8 | |
| SCHEMBL23794423 | 0.89 | MAPK1 (0.74) | CA1CA2MAPK1HDAC3HDAC4 | |
| SCHEMBL30432125 | 0.87 | MAPK1 (0.83) | CA1CA2MAPK1HDAC3HDAC4 | |
| SCHEMBL5658185 | 0.86 | MAPK1 (0.87) | CA1CA2MAPK1HDAC3HDAC4 | |
| SCHEMBL1161862 | 0.86 | GFER (0.64) | MAPK1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7742564 | 0.84 | MAPK1 (0.68) | CA1CA2MAPK1HDAC3HDAC4 | |
| Betamipron SCHEMBL605899 | 0.84 | PRSS1 (0.70) | CA1CA2MAPK1HDAC3HDAC4 | |
| Betamipron SCHEMBL4498475 | 0.84 | PRSS1 (0.70) | CA1CA2MAPK1HDAC3HDAC4 | |
| SCHEMBL5625471 | 0.83 | CYP1A2 (0.66) | CA1CA2MAPK1HDAC3HDAC4 | |
| SCHEMBL2644934 | 0.83 | CA1 (0.61) | CA1CA2MAPK1SIRT5NME4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4397672-A1 | COMPOUND AND LABELED BIOMATERIAL USING SAME | FUJIFILM Corporation (JP) | 2024-07-10 | — | — | EP | disclosed |
| WO-2024143263-A1 | FLUORESCENCE INTENSITY ENHANCING AGENT, METHOD FOR ENHANCING FLUORESCENCE INTENSITY OF FLUORESCENTLY LABELED TARGET BIOLOGICAL MATERIAL, AND FLUORESCENCE DETECTION KIT | 富士フイルム株式会社 | 2024-07-04 | — | — | WO | disclosed |
| US-8937090-B2 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO COMPANY, LTD. (JP) | 2015-01-20 | — | — | US | disclosed |
| US-8673980-B2 | Closthioamides, compositions, and methods for treating bacterial or fungal infections or cancer | LEIBNIZ-INSTITUT FUER NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE (DE) | 2014-03-18 | — | — | US | disclosed |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | SHISEIDO COMPANY, LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| WO-2011050994-A2 | CLOSTHIOAMIDES | LEIBNIZ-INSTITUT FÜR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE (DE) | 2011-05-05 | — | — | WO | disclosed |
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| EP-1941861-A1 | WRINKLE-IMPROVING AGENT | Shiseido Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| EP-1880711-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | CA1 4651/4885CA2 2941/4885MAPK1 2330/4885 |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | CUTA, AAAS, NUP160 | CA1 1466/4885CA2 876/4885MAPK1 2393/4885 |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | CA1 4609/4885CA2 3261/4885MAPK1 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.